Dravet syndrome: Treatment options and management of prolonged seizures

Epilepsy

Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial

Lancet.

Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, Devinsky O, Cross JH, Guerrini R, Talwar D, Miller I, Farfel G, Galer BS, Gammaitoni A, Mistry A, Morrison G, Lock M, Agarwal A, Lai WW, Ceulemans B, FAiRE DS Study Group.

doi: 10.1016/S0140-6736(19)32500-0.

Epilepsy

Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial

Epilepsia.

Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, Roberts C

doi: 10.1111/epi.

Epilepsy

Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in German

Epilepsia

Strzelczyk A, Pringsheim M, Mayer T, Polster T, Klotz KA, Muhle H, Alber M, Trollmann R, Spors H, Kluger G, Kurlemann G, Schubert-Bast S

doi: 10.1111/epi.17034

Epilepsy

Epilepsy with myoclonic-atonic seizures (Doose syndrome): Clarification of diagnosis and treatment options through a large retrospective multicenter cohort

Epilepsia

Nickels K, Kossoff EH, Eschbach K, Joshi C

doi: 10.1111/epi.16752

Epilepsy

A prospective open‐label trial of a CBD/THC cannabis oil in dravet syndrome

Ann Clin Transl Neurol.

McCoy B, Wang L, Zak M, Al‐Mehmadi S, Kabir N, Alhadid K, McDonald K, Zhang G, Sharma R, Whitney R, Sinopoli K, Snead III OC

doi: org/10.1002/acn3.621.

Epilepsy

A multicenter, matched case-control analysis comparing burden-of-illness in Dravet syndrome to refractory epilepsy and seizure remission in patients and caregivers in Germany

Epilepsia.

Strzelczyk A, Schubert-Bast S, Bast T, Bettendorf U, Fiedler B, Hamer HM, Herting A, Kalski M, Kay L, Kieslich M, Klein KM, Kluger G, Kurlemann G, Mayer T, Neubauer BA, Polster T, von Spiczak S, Stephani U, Trollmann R, Wiemer-Kruel A, Wolff M, Irwin J, Carroll J, Pritchard C, Rosenow F

doi: 10.1111/epi.16099.

Further Publications NeurologyFurther Publications Psychiatry

Towards a better diagnosis and treatment of Rett syndrome: a model synaptic disorder

Brain.

Banerjee A, Miller MT, Li K, Sur M, Kaufmann WE

doi: 10.1093/brain/awy323.

Epilepsy

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome

N Engl J Med.

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE Study Group

doi: 10.1056/NEJMoa1714631.

Epilepsy

Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy

Epilepsia.

Brikell I, Chen Q, Kuja-Halkola R, D'Onofrio BM, Wiggs KK, Lichtenstein P, Almqvist C, Quinn PD, Chang Z, Larsson H

doi: 10.1111/epi.

Related content

Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial

Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial

Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in German

Epilepsy with myoclonic-atonic seizures (Doose syndrome): Clarification of diagnosis and treatment options through a large retrospective multicenter cohort

A prospective open‐label trial of a CBD/THC cannabis oil in dravet syndrome

A multicenter, matched case-control analysis comparing burden-of-illness in Dravet syndrome to refractory epilepsy and seizure remission in patients and caregivers in Germany

Towards a better diagnosis and treatment of Rett syndrome: a model synaptic disorder

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome

Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy